Enteral feeding during indomethacin and ibuprofen treatment of a patent ductus arteriosus

J Pediatr. 2013 Aug;163(2):406-11. doi: 10.1016/j.jpeds.2013.01.057. Epub 2013 Mar 6.

Abstract

Objective: To test the hypothesis that infants who are just being introduced to enteral feedings will advance to full enteral nutrition at a faster rate if they receive "trophic" (15 mL/kg/d) enteral feedings while receiving indomethacin or ibuprofen treatment for patent ductus arteriosus.

Study design: Infants were eligible for the study if they were 23(1/7)-30(6/7) weeks' gestation, weighed 401-1250 g at birth, received maximum enteral volumes ≤60 mL/kg/d, and were about to be treated with indomethacin or ibuprofen. A standardized "feeding advance regimen" and guidelines for managing feeding intolerance were followed at each site (N = 13).

Results: Infants (N = 177, 26.3 ± 1.9 weeks' mean ± SD gestation) were randomized at 6.5 ± 3.9 days to receive "trophic" feeds ("feeding" group, n = 81: indomethacin 80%, ibuprofen 20%) or no feeds ("fasting [nil per os]" group, n = 96: indomethacin 75%, ibuprofen 25%) during the drug administration period. Maximum daily enteral volumes before study entry were 14 ± 15 mL/kg/d. After drug treatment, infants randomized to the "feeding" arm required fewer days to reach the study's feeding volume end point (120 mL/kg/d). Although the enteral feeding end point was reached at an earlier postnatal age, the age at which central venous lines were removed did not differ between the 2 groups. There were no differences between the 2 groups in the incidence of infection, necrotizing enterocolitis, spontaneous intestinal perforation, or other neonatal morbidities.

Conclusion: Infants required less time to reach the feeding volume end point if they were given "trophic" enteral feedings when they received indomethacin or ibuprofen treatments.

Trial registration: ClinicalTrials.gov NCT00728117.

Keywords: BPD; Bronchopulmonary dysplasia; NEC; Necrotizing enterocolitis; Nil per os; PDA; Patent ductus arteriosus; npo.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Combined Modality Therapy
  • Ductus Arteriosus, Patent / drug therapy
  • Ductus Arteriosus, Patent / therapy*
  • Enteral Nutrition*
  • Female
  • Humans
  • Ibuprofen / therapeutic use*
  • Indomethacin / therapeutic use*
  • Infant, Newborn
  • Male
  • Prospective Studies
  • Time Factors

Substances

  • Ibuprofen
  • Indomethacin

Associated data

  • ClinicalTrials.gov/NCT00728117